A phase II proof of concept trial of cenicriviroc in combination with evogliptin in non-alcoholic steatohepatitis
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Cenicriviroc (Primary) ; Evogliptin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- 01 Nov 2016 This trial was planned by Tobira Therapeutics which has now acquired by Allergan according to a Allergan media release.
- 01 Sep 2016 New trial record
- 09 Aug 2016 According to a Tobira Therapeutics media release, this trial is expected to initiate in 2017.